Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Weigelt B, Zamarin D. Brodeur MN, et al. Among authors: zamarin d. bioRxiv [Preprint]. 2023 Aug 11:2023.08.08.552544. doi: 10.1101/2023.08.08.552544. bioRxiv. 2023. Update in: Sci Adv. 2024 Dec 6;10(49):eadk4851. doi: 10.1126/sciadv.adk4851 PMID: 37609261 Free PMC article. Updated. Preprint.
Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer.
McPherson A, Vázquez-García I, Myers MA, Zatzman M, Al-Rawi D, Weiner A, Freeman S, Mohibullah N, Satas G, Williams MJ, Ceglia N, Zhang AW, Li J, Lim JLP, Wu M, Choi S, Havasov E, Grewal D, Shi H, Kim M, Schwarz R, Kaufmann T, Dinh KN, Uhlitz F, Tran J, Wu Y, Patel R, Ramakrishnan S, Kim D, Clarke J, Green H, Ali E, DiBona M, Varice N, Kundra R, Broach V, Gardner GJ, Roche KL, Sonoda Y, Zivanovic O, Kim SH, Grisham RN, Liu YL, Viale A, Rusk N, Lakhman Y, Ellenson LH, Tavaré S, Aparicio S, Chi DS, Aghajanian C, Abu-Rustum NR, Friedman CF, Zamarin D, Weigelt B, Bakhoum SF, Shah SP. McPherson A, et al. Among authors: zamarin d. bioRxiv [Preprint]. 2024 Jul 15:2024.07.11.602772. doi: 10.1101/2024.07.11.602772. bioRxiv. 2024. PMID: 39071261 Free PMC article. Preprint.
Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA.
Williams MJ, Vázquez-García I, Tam G, Wu M, Varice N, Havasov E, Shi H, Satas G, Lees HJ, Lee JJ, Myers MA, Zatzman M, Rusk N, Ali E, Shah RH, Berger MF, Mohibullah N, Lakhman Y, Chi DS, Abu-Rustum NR, Aghajanian C, McPherson A, Zamarin D, Loomis B, Weigelt B, Friedman CF, Shah SP. Williams MJ, et al. Among authors: zamarin d. bioRxiv [Preprint]. 2024 Aug 23:2024.08.21.609031. doi: 10.1101/2024.08.21.609031. bioRxiv. 2024. PMID: 39229105 Free PMC article. Preprint.
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche RP, Qu R, Rosenberg L, Hamard PJ, Bykov Y, Green H, Gusain L, Chiappinelli KB, Ozsoy MA, Chui MH, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Vabret N, Weigelt B, Zamarin D. Brodeur MN, et al. Among authors: zamarin d. Sci Adv. 2024 Dec 6;10(49):eadk4851. doi: 10.1126/sciadv.adk4851. Epub 2024 Dec 4. Sci Adv. 2024. PMID: 39630912 Free PMC article.
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.
Davar D, Carneiro BA, Dy GK, Sheth S, Borad MJ, Harrington KJ, Patel SP, Galanis E, Samson A, Agrawal S, Chen Z, Fan C, Gong M, Burton J, Tu E, Durham N, Laubscher K, Arnaldez F, Zamarin D. Davar D, et al. Among authors: zamarin d. J Immunother Cancer. 2024 Nov 17;12(11):e009336. doi: 10.1136/jitc-2024-009336. J Immunother Cancer. 2024. PMID: 39551600 Free PMC article. Clinical Trial.
Ovarian cancer-derived IL-4 promotes immunotherapy resistance.
Mollaoglu G, Tepper A, Falcomatà C, Potak HT, Pia L, Amabile A, Mateus-Tique J, Rabinovich N, Park MD, LaMarche NM, Brody R, Browning L, Lin JR, Zamarin D, Sorger PK, Santagata S, Merad M, Baccarini A, Brown BD. Mollaoglu G, et al. Among authors: zamarin d. Cell. 2024 Dec 26;187(26):7492-7510.e22. doi: 10.1016/j.cell.2024.10.006. Epub 2024 Oct 30. Cell. 2024. PMID: 39481380
Transgelin 2 guards T cell lipid metabolism and antitumour function.
Hwang SM, Awasthi D, Jeong J, Sandoval TA, Chae CS, Ramos Y, Tan C, Marin Falco M, Salvagno C, Emmanuelli A, McBain IT, Mishra B, Ivashkiv LB, Zamarin D, Cantillo E, Chapman-Davis E, Holcomb K, Morales DK, Yu X, Rodriguez PC, Conejo-Garcia JR, Kaczocha M, Vähärautio A, Song M, Cubillos-Ruiz JR. Hwang SM, et al. Among authors: zamarin d. Nature. 2024 Nov;635(8040):1010-1018. doi: 10.1038/s41586-024-08071-y. Epub 2024 Oct 23. Nature. 2024. PMID: 39443795
2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both.
Rios-Doria E, Abu-Rustum NR, Glaser G, McGree M, Eriksson AG, Pham M, Soliman P, Ataseven B, Alektiar K, Zamarin D, Leitao ML Jr, Mueller J. Rios-Doria E, et al. Among authors: zamarin d. Int J Gynecol Cancer. 2024 Oct 7;34(10):1580-1587. doi: 10.1136/ijgc-2024-005567. Int J Gynecol Cancer. 2024. PMID: 39074930
Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer.
Sandoval TA, Salvagno C, Chae CS, Awasthi D, Giovanelli P, Marin Falco M, Hwang SM, Teran-Cabanillas E, Suominen L, Yamazaki T, Kuo HH, Moyer JE, Martin ML, Manohar J, Kim K, Sierra MA, Ramos Y, Tan C, Emmanuelli A, Song M, Morales DK, Zamarin D, Frey MK, Cantillo E, Chapman-Davis E, Holcomb K, Mason CE, Galluzzi L, Ni Zhou Z, Vähärautio A, Cloonan SM, Cubillos-Ruiz JR. Sandoval TA, et al. Among authors: zamarin d. Cancer Discov. 2024 Oct 4;14(10):1901-1921. doi: 10.1158/2159-8290.CD-23-1451. Cancer Discov. 2024. PMID: 39073085
145 results